
|Videos|August 16, 2017
Rutgers Researchers Develop New MRSA Prodrug: Can the Pathogen Gain Resistance?
Author(s)Contagion Editorial Staff
Daniel Pilch, PhD, discusses the potential of Staphylococcus aureus to develop resistance to TXA709.
Advertisement
Daniel Pilch, PhD, associate professor in the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School, co-founder of TAXIS Pharmaceuticals, breaks down the process of how Staphylococcus aureus (S. aureus) is able to gain resistance to methicillin. Dr. Pilch also explains if the pathogen can gain resistance to a new prodrug he helped develop: TXA709.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
Working in a Hot Zone: Building Trust With Local Communities, Addressing Gaps In Preparedness
2
CDC Awards Grant to Study Neonatal Hepatitis B Vaccination Outcomes in Guinea-Bissau
3
Emory Healthcare: Melding Critical Care, Infectious Diseases, and Disaster Preparedness Together
4
Vir Grants Norgine Commercial Rights to Hepatitis Delta Therapy in Europe, Australia, and New Zealand
5

















































































































































































































































































